294.55
Beone Medicines Ltd Adr stock is traded at $294.55, with a volume of 893.45K.
It is up +1.45% in the last 24 hours and up +16.52% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
See More
Previous Close:
$290.35
Open:
$297.5
24h Volume:
893.45K
Relative Volume:
2.33
Market Cap:
$32.28B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-47.20
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
+17.68%
1M Performance:
+16.52%
6M Performance:
+40.21%
1Y Performance:
+0.00%
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare ONC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
Dec-03-24 | Resumed | Morgan Stanley | Overweight |
Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
Feb-06-24 | Resumed | JP Morgan | Overweight |
Sep-12-23 | Initiated | Macquarie | Outperform |
Aug-17-23 | Initiated | Jefferies | Buy |
Jul-17-23 | Initiated | Citigroup | Buy |
Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
Jan-12-23 | Initiated | Daiwa Securities | Buy |
Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Aug-09-22 | Resumed | JP Morgan | Overweight |
Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-07-22 | Initiated | Deutsche Bank | Buy |
Oct-12-21 | Initiated | Bernstein | Outperform |
Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
Mar-08-21 | Initiated | China Renaissance | Buy |
Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines Ltd.Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? - MSN
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $330.00 at Morgan Stanley - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Down 3.6% After Insider Selling - Defense World
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 630 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat
Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com
BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
LLY Stock Quote Price and Forecast - CNN
H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India
China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India
China approves novel HER2-targeted therapy for BTC - Investing.com Australia
BeiGene completes corporate re-domiciliation to Switzerland - Investing.com
BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com Nigeria
Daiwa Raises BEIGENE's TP to HKD180; Brukinsa Sales Growth Outpaces Competitors - AASTOCKS.com
BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India
Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX
BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins patent challenge against Pharmacyclics - Investing.com
BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions - Zacks Investment Research
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beone Medicines Ltd Adr Stock (ONC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
OYLER JOHN | Chief Executive Officer |
Jul 09 '25 |
Sale |
253.38 |
27,802 |
7,044,591 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):